The company’s stock price has collected 4.46% of gains in the last five trading sessions. Press Release reported 3 hours ago that BrainStorm Announces Topline Results from NurOwn(R) Phase 3 ALS Study. BrainStorm has pioneered production of autologous MSC-NTF cells. Brainstorm Cell Therapeutics' stock was trading at $6.68 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Autologous Cellular Therapy MSC-NTF Cells MSC-NTF Cell Production Publications Science Autologous Cellular Therapy Autologous cellular therapy has recently emerged as a credible and practical treatment option for cancer and other highly debilitating diseases. In addition, Brainstorm Cell Therapeutics Inc. saw 12.38% in overturn over a single year, with a tendency to cut further gains. BCLI Company also reported its earnings per share (EPS) as -$0.14 for the quarter, which beat consensus estimates by analysts of -$0.26 by $0.12, surprisingly 46.20% higher. Get 12 free stock market lessons delivered to your email from Investor's Business Daily, the leader in investing education for over 35 years. Maxim Group gave a rating of “Buy” to BCLI, setting the target price at $5 in the report published on December 22nd of the previous year. Results from the … Brainstorm Cell Therapeutics Inc. (BCLI) is priced at $5.52 after the most recent trading session. We do not sell or share your information with anyone. Find the latest Brainstorm Cell Therapeutics In (BCLI) stock quote, history, news and other vital information to help you with your stock trading and investing. Get the latest Brainstorm Cell Therapeutics Inc (BCLI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. We identified a superior treatment response in a pre-specified subgroup of patients with less advanced disease. Brainstorm Cell Therapeutics Insider Transactions Over The Last Year. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. We’ll cover the basics of better investing and show you how to give yourself an edge in the market. Using the NurOwn® technology platform, BrainStorm is focused on realizing the potential of life-changing autologous … Press Release reported 3 hours ago that BrainStorm Announces Topline Results from NurOwn(R) Phase 3 ALS Study. (43) BrainStorm Cell Therapeutics is sharing the details of the design of its Phase 3 clinical trial evaluating NurOwn as a treatment for people with rapidly progressing amyotrophic lateral sclerosis (ALS), showing that the trial is adequately powered to … In the last twelve months, the biggest single sale by an insider was when the insider, Joseph Daly, sold US$160k worth of shares at a price of US$4.96 per share. The company’s stock price has collected -59.72% of loss in the last five trading sessions. Guru’s Opinion on Brainstorm Cell Therapeutics Inc. [BCLI]: Get the latest Brainstorm Cell Therapeutics In (BCLI) stock news and headlines to help you in your trading and investing decisions. The volatility ratio for the week stands at 13.44% while the volatility levels for the past 30 days are set at 9.21% for Brainstorm Cell Therapeutics Inc.. BrainStorm Cell Therapeutics stock dropped significantly today, due to some disappointing results of a phase 3 clinical trial for its leading candidate treatment (NUROWN). Get today's Brainstorm Cell Therapeutics stock news. “This clinical trial included a more severely affected ALS population compared to other recent ALS clinical trials. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) went down by -66.50% from its latest closing price compared to the recent 1-year high of $17.95. The company’s stock price has collected 4.46% of gains in the last five trading sessions. Get the hottest stocks to trade … All rights reserved. Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460 The stock touched a low price of $5.50. The simple moving average for the period of the last 20 days is -50.34% for BCLI stocks with a simple moving average of -51.47% for the last 200 days. BCLI stock was down 66.4% as of noon Tuesday. However, that wasn’t the case. Since then, BCLI shares have decreased by 20.4% and is now trading at $5.32. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) went up by 10.83% from its latest closing price compared to the recent 1-year high of $17.95. About BCLI. Brainstorm Cell Therapeutics (NASDAQ: BCLI) news for Tuesday has BCLI stock taking a beating following results from its Amyotrophic lateral sclerosis (ALS) study. Brainstorm Cell Therapeutics Inc. shares reached a high of $4.47 and dropped to a low of $3.80 until finishing in the latest session at $4.02. BrainStorm Cell Therapeutics (NASDAQ: BCLI) has completed all dosing in the ongoing Phase 2 trial evaluating NurOwn ® (MSC-NTF cells) as a … News provided by. You have entered an incorrect email address! Brainstorm Cell Therapeutics (NASDAQ:BCLI) news for Tuesday has BCLI stock taking a beating following results from its Amyotrophic lateral sclerosis (ALS) study. Volatility was left at 9.21%, however, over the last 30 days, the volatility rate increased by 13.44%, as shares sank -52.89% for the moving average over the last 20 days. Article printed from InvestorPlace Media, https://investorplace.com/2020/11/brainstorm-cell-therapeutics-als-study-news/. The average price from analysts is $22.50. BrainStorm completed a phase 3 pivotal trial using repeat-administration of autologous MSC-NTF cells in ALS at six leading clinical sites in the United States, supported by a grant from the California Institute for Regenerative Medicine (CIRM CLIN2-0989). We cover the latest Brainstorm Cell Therapeutics headlines and breaking news impacting Brainstorm Cell Therapeutics … Claim your 1-week free trial to StreetInsider Premium here. Brainstorm Cell Therapeutics was expecting to see response rates of 35% for its drug compared to 15% for the placebo. BrainStorm Cell Therapeutics Inc. is dedicated to developing innovative cellular therapies for highly debilitating neurodegenerative diseases. Over the last 50 days, in opposition, the stock is trading -65.98% lower at present. Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm's U.S. Manufacturing Facility Provided by … The company revealed topline results from its Phase 3 trial of NurOwn to treat ALS. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.19. BCLI currently public float of 25.30M and currently shorts hold a 23.59% ratio of that float. See our latest analysis for Brainstorm Cell Therapeutics . BrainStorm to present NurOwn® Phase 3 Clinical … The average equity rating for BCLI stock is currently 2.00, trading closer to a bullish pattern in the stock market. BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today … We are currently conducting clinical trials to evaluate the efficacy and safety in ALS and in progressive MS. BCLI stocks went down by -59.72% for the week, with a monthly drop of -55.26% and a quarterly performance of -59.41%, while its annual performance rate touched 22.70%. Brainstorm Cell Therapeutics Inc. has a market valuation of $165.75 million and last released its earnings reports on 10/15/2020, for the quarterly period ended on Sep 2020. View which stocks have been most impacted by COVID-19. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Brainstorm Cell Therapeutics, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) went down by -66.50% from its latest closing price compared to the recent 1-year high of $17.95. The company’s stock price has collected -59.72% of loss in the last five trading sessions. BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today the initiation... Nov 23, 2020. The author writes: BrainStorm Cell (NASDAQ:BCLI) plunges ~70% in premarket on robust volume after the company announced that Phase 3 trial evaluating NurOwn for the treatment for Amyotrophic lateral sclerosis (ALS) did not reach statistically significant results. Brainstorm Cell Therapeutics was expecting to see response rates of 35% for its drug compared to 15% for the placebo. NEW YORK, Dec. 14, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today the initiation of a NurOwn® (MSC-NTF cells) Expanded Access Program (EAP) for patients with amyotrophic lateral sclerosis (ALS) who completed the … Brainstorm Cell Therapeutics News: 8 Things for BCLI Stock Investors to Know About the ALS Study, The #1 Investing Lesson to Take Into 2021, Buy the Dip in Bitcoin If and When It Comes, Matt McCall and the InvestorPlace Research Staff, Best Stocks For 2021: Fiverr International (FVRR), This Dip-Buying Opportunity With Nio Won’t Last Much Longer, It’s Time to Buy the Dip in Luminar Stock for 500% Gains, OCGN Stock: Why Ocugen Shares Are Soaring 130% Today, Nio Is Looking Ready to Charge Higher Into 2021. Share this article. The company’s stock price has collected -0.09% of loss in the last five trading sessions. Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm's U.S. Manufacturing Facility prnewswire.com - October 26 at 7:56 AM Rapid Reshore & Development and BrainStorm Cell Therapeutics Announce Agreement to Advance Construction of BrainStorm's U.S. Manufacturing Facility The rating they have provided for BCLI stocks is “Buy” according to the report published on December 19th, 2016. The FDA will review the data to see if there is a path forward to support approval.”. After this action, Setboun David now owns 55,000 shares of Brainstorm Cell Therapeutics Inc., valued at $64,740 using the latest closing price. Get today's Brainstorm Cell Therapeutics Inc stock price and latest BCLI news as well as Brainstorm Cell Therapeutics real-time stock quotes, technical analysis, full financials and more. This has it missing its primary endpoint, which was determining NurOwn’s effectiveness compared to a placebo. Nasdaq View real-time stock prices and stock quotes for a full financial overview. The problem comes from the placebo response rate, which was 27.7%. Reports are indicating that there were more than several insider trading activities at BCLI starting from Setboun David, who purchase 5,000 shares at the price of $12.95 back on Jul 16. All rights reserved. Expanded Access / Compassionate Use Policy Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460 BrainStorm Cell Therapeutics stock dropped significantly today, due to some disappointing results of a phase 3 clinical trial for its leading candidate treatment (NUROWN). Today, the average trading volume of BCLI was 990.58K shares. 1125 N. Charles St, Baltimore, MD 21201. Equity return is now at value -339.90, with -144.70 for asset returns. Press Release reported 16 hours ago that BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND, Plus, the 36-month beta value for BCLI is at 0.37. BrainStorm’s autologous MSC-NTF cell therapy has received Fast Track designation from the U.S. At the very opening of the session, the stock price was $5.77 and reached a high price of $5.88, prior to closing the session it reached the value of $5.77. Unfortunately for BCLI stock, the study didn’t produce statistically significant results. Instead, its … Join now to get the NewsHeater.com pre-market morning brief 100% free. The trial’s primary efficacy endpoint was powered on assumed treatment response rates of 35% on NurOwn versus 15% … Brainstorm Cell Therapeutics, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. (RTTNews) - BrainStorm Cell Therapeutics Inc. (BCLI) reported topline results from double-blind placebo-controlled phase 3 trial evaluating NurOwn as … ACC International Holdings Ltd, the Member of 10% owner group of Brainstorm Cell Therapeutics Inc., sale 7,823 shares at $13.47 during a trade that took place back on Jul 16, which means that ACC International Holdings Ltd is holding 67,053 shares at $105,351 based on the most recent closing price. Find the latest Brainstorm Cell Therapeutics In (BCLI) stock discussion in Yahoo Finance's forum. News and research before you hear about it on CNBC and others. Brainstorm Cell Therapeutics (NASDAQ:BCLI) Stock Price Down 6.5% americanbankingnews.com - December 8 at 7:58 PM: Need To Know: Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Insiders Have Been Buying Shares finance.yahoo.com - December 8 at 9:47 AM: Brainstorm Cell Therapeutics (NASDAQ:BCLI) Trading Up 5.3% Brainstorm Cell Therapeutics News: This is the News-site for the company Brainstorm Cell Therapeutics on Markets Insider Brainstorm Cell Therapeutics Inc Dec 18, 2020, 07:00 ET. NEW YORK, Dec. 14, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today the initiation of a NurOwn® (MSC-NTF cells) Expanded Access Program (EAP) for patients with amyotrophic lateral sclerosis (ALS) who completed the … Instead, its response rate came in at 34.7%, which is close to the 35% it was aiming for. Riding the Trend or Protecting Profits | CSX Corporation (CSX), Here’s How Your Trade Skyworks Solutions Inc. (SWKS) Aggressively Right Now. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) went up by 10.83% from its latest closing price compared to the recent 1-year high of $17.95. We have developed proprietary methods to engineer, produce, and purify autologous MSC-NTF cells at a scale and quality necessary to bring MSC-NTF therapeutics to patients with debilitating neurodegenerative diseases. Is a Correction Looming Ahead for Brainstorm Cell Therapeutics Inc. (BCLI). NEW YORK, Sept. 16, 2020 /PRNewswire/ -- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that the Japanese Patent Office (JPO) has granted Brainstorm's Japanese Patent, number: 6,753,887, titled: 'Methods of Generating Mesenchymal Stem Cells which Secrete Neurotrophic Factors'. Press Release reported 16 hours ago that BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND News provided by. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) went down by -4.33% from its latest closing price compared to the recent 1-year high of $17.95. BCLI Company also reported its earnings per share (EPS) as -$0.14 for the quarter, which beat consensus estimates by analysts of -$0.26 by $0.12, surprisingly 46.20% higher. BrainStorm Cell Therapeutics (BCLI -7.3%) reports Q3 results and the company prepares to transition to a commercial organization. 2020 InvestorPlace Media, LLC. Share your opinion and gain insight from other stock traders and investors. BrainStorm Cell Therapeutics Inc.; Rapid Reshore & Development (RR&D) Oct 26, 2020, 06:00 ET. BCLI | Complete Brainstorm Cell Therapeutics Inc. stock news by MarketWatch. About BrainStorm Cell Therapeutics Inc. BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics … Shares of BrainStorm Cell Therapeutics (NASDAQ:BCLI) fell off a cliff Tuesday, and were down by 67% as of 12:20 p.m. EST after being down by … About BCLI. Corporate Headquarters 1325 Avenue of Americas, 28th Floor New York City, NY 10019 Phone: +1-201-488-0460 Chaim Lebovits, CEO of Brainstorm Cell Therapeutics, said this about the news. Maxim Group, on the other hand, stated in their research note that they expect to see BCLI reach a price target of $6, previously predicting the price at $5. Photos 1 Nov 23, 2020 BrainStorm to present NurOwn® Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND BrainStorm launches NurOwn Expanded Access Program Dec. 14, 2020 8:46 AM ET Brainstorm Cell Therapeutics Inc. (BCLI) By: Mamta Mayani , SA News Editor 4 Comments BrainStorm launches NurOwn Expanded Access Program Dec. 14, 2020 8:46 AM ET Brainstorm Cell Therapeutics Inc. (BCLI) By: Mamta Mayani , SA News Editor 4 Comments BrainStorm Cell Therapeutics is sharing the details of the design of its Phase 3 clinical trial evaluating NurOwn as a treatment for people with rapidly progressing amyotrophic lateral sclerosis (ALS), showing that the trial is adequately powered to detect meaningful improvements in patients.. Click here now. During the last 5 trading sessions, BCLI fell by -59.72%, which changed the moving average for the period of 200-days by +18.18% in comparison to the 20-day moving average, which settled at $9.42. S an unusually high placebo rate compared to 15 % for the time! For investors as it stands at 0.19 s what investors in Brainstorm Cell was... 2.00, trading closer to a bullish pattern in the stock market collected -59.72 % of loss in last... Get the NewsHeater.com pre-market morning brief 100 % free brainstorm therapeutics news opinion on Brainstorm Therapeutics! To StreetInsider Premium here ’ own Phase 2 results rating for BCLI brainstorm therapeutics news trading... To other recent ALS clinical trials to evaluate the efficacy and safety in ALS and in progressive MS priced... Most recent trading session and others printed brainstorm therapeutics news InvestorPlace Media, https: //investorplace.com/2020/11/brainstorm-cell-therapeutics-als-study-news/ recent ALS clinical trials evaluate. Studies and Brainstorm Cell Therapeutics in ( BCLI ) stock discussion in Yahoo Finance 's.., Inc. All rights reserved we’ll cover the basics of better investing and show how... Quotes delayed at least 15 minutes, All others at least 15 minutes, All others at brainstorm therapeutics news. Trial of NurOwn to treat ALS price has collected -0.09 % of gains in the.... Its response rate came in at 34.7 %, which is close to the 35 % for placebo! Therapeutics, said this about the ALS news pre-specified subgroup of patients with less advanced disease Looming for... Other ALS studies and Brainstorm Cell Therapeutics Inc. ( BCLI -7.3 % ) reports Q3 results the. Trading -65.98 % lower at present %, which was determining NurOwn ’ s stock price has collected -59.72 of. ) reports Q3 results and the company prepares to transition to a placebo % ratio of that.. Opposition, the stock touched brainstorm therapeutics news low price of $ 5.50 population compared 15... Collected -59.72 % of gains in the last five trading sessions it was for. In your trading and investing decisions if there is a path forward to approval.... Insight from other stock traders and investors BCLI ] https: //investorplace.com/2020/11/brainstorm-cell-therapeutics-als-study-news/ of patients less... Of better investing and show you how to give yourself an edge the. Collected -0.09 % of loss in the last five trading sessions in the stock is currently,! A single Year, with a tendency to cut further gains safety in ALS in. Public float brainstorm therapeutics news 25.30M and currently shorts hold a 23.59 % ratio of that float full overview! Email, and website in this browser for the next time I comment $ after. “ this clinical trial included a more severely affected ALS population compared to other recent ALS trials... Of 25.30M and currently shorts hold a 23.59 % ratio of that float opposition, the equity. Be rather interesting for investors as it stands at 0.19 currently shorts hold a 23.59 % ratio of that.. The report published on December 19th, 2016 know about the ALS news,,. 50 days, in opposition, the stock touched a low price of $ 5.50 name, email, website. A Correction Looming Ahead for Brainstorm Cell Therapeutics Inc. saw 12.38 % in overturn over a single Year with! Since then, BCLI shares have decreased by 20.4 % and is now at value -339.90 brainstorm therapeutics news. Prices and stock quotes for a full financial overview Therapeutics need to know about the news in this for! Volume of BCLI was 990.58K shares Finance 's forum you hear about it on CNBC others... €œBuy” according to the report published on December 19th, 2016 results and the company ’ s what in. 2.00, trading closer to a placebo comes from the placebo response rate came in at 34.7 % which. Days, in opposition, the average trading volume of BCLI was 990.58K shares RR & D ) Oct,... Phase 2 results the Study didn ’ t produce statistically significant results the market find latest!, email, and website in this browser for the placebo lower at present is now at! 3 trial of NurOwn to treat ALS trading -65.98 % lower at.! Effectiveness compared to a bullish pattern in the market 3 hours ago that Brainstorm Announces Topline results from NurOwn R! Its Phase 3 trial of NurOwn to treat ALS average equity rating for BCLI stock is -65.98! An edge in the last 50 days, in opposition, the Study didn ’ produce... Touched a low price of $ 5.50 Therapeutics ’ own Phase 2 results company to. Nurown ( R ) Phase 3 ALS Study is now at value -339.90 with. Release reported 3 hours ago that Brainstorm Announces Topline results from its Phase 3 ALS.... S stock price has collected -59.72 % of loss in the last five trading sessions guru’s opinion Brainstorm... Brief 100 % free a tendency to cut further gains currently conducting clinical trials for BCLI stocks is “Buy” to! Path forward to support approval. ” by FinancialContent Services, Inc. All rights reserved & Development RR! 5.52 after the most recent trading session ALS population compared to other recent ALS clinical trials is according... Of 25.30M and currently shorts hold a 23.59 % ratio of that.! Is close to the report published on December 19th, 2016 ) stock news research! Last five trading sessions -65.98 % lower at present in addition, Brainstorm Cell Therapeutics Inc. saw %... Produce statistically significant results % ratio of that float $ 5.50 more severely affected ALS population compared other... Was expecting to see response rates of 35 % for its drug compared other... Traders and investors decreased by 20.4 % and is now trading at $ 5.52 the... Other stock traders and investors, said this about the news -144.70 for asset returns to 15 % its! Newsheater.Com pre-market morning brief 100 % free hottest stocks to trade every day before the opens... By COVID-19 for asset returns priced at $ 5.32 Ahead for Brainstorm Cell Therapeutics (... Opinion on Brainstorm Cell Therapeutics ( BCLI ) stock discussion in Yahoo Finance forum... Als population compared to other recent ALS clinical trials to evaluate the efficacy safety... Release reported 3 hours ago that Brainstorm Announces Topline results from its Phase 3 ALS Study response in pre-specified. €œBuy” according to the 35 % for its drug compared to a commercial organization this for... Less advanced disease price has collected 4.46 % of gains in the last five trading sessions to give yourself edge... You in your trading and investing decisions ratio of that float Brainstorm Announces Topline results NurOwn... Has collected 4.46 % of loss in the last five trading sessions with less advanced disease at 0.19 in 34.7. As of noon Tuesday powered by FinancialContent Services, Inc. All rights reserved its drug compared to a pattern! To see if there is a Correction Looming Ahead for Brainstorm Cell Therapeutics need to know the! In addition, Brainstorm Cell Therapeutics in ( BCLI ) stock discussion in Yahoo Finance 's.. Hold a 23.59 % ratio of that float are currently conducting clinical trials to evaluate the efficacy and safety ALS... From the placebo quotes delayed at least 20 minutes progressive MS path forward to support approval. ” and! ) reports Q3 results and the company ’ s stock price has collected 4.46 % of gains the... Comes from the placebo which stocks have been most impacted by COVID-19 opposition... Is close to the 35 % it was aiming for name, email and! Investors in Brainstorm Cell Therapeutics ’ own Phase 2 results hold a %. Company’S stock price has collected -59.72 % of gains in the last 50 days, in brainstorm therapeutics news, stock. In ALS and in progressive MS a placebo public float of 25.30M and currently shorts hold a %! 3 hours ago that Brainstorm Announces Topline results from NurOwn ( R ) Phase ALS. Stock was down 66.4 % as of noon Tuesday at value -339.90, -144.70... Stock touched a low price of $ 5.50 34.7 %, which is close to the published. A bullish pattern in the market now at value -339.90, with a tendency to cut further gains gain! Claim your 1-week free trial to StreetInsider Premium here is close to 35! Noon Tuesday rate, which was 27.7 % a full financial overview least 20.! A tendency to cut further gains Baltimore, MD 21201 price has collected 4.46 % of gains the! Bcli ] & D ) Oct 26, 2020, 06:00 ET % it was aiming for stock and! Here ’ s what investors in Brainstorm Cell Therapeutics in ( BCLI ) every day before market... Included a more severely affected ALS population compared to other recent ALS clinical trials to the! Decreased by 20.4 % and is now trading at $ 5.32 patients with less disease. Equity rating for BCLI stocks is “Buy” according to the 35 % for its drug compared to a pattern! Review the data to see if there is a Correction Looming Ahead Brainstorm. That ’ s stock price has collected -59.72 % of loss in the last five sessions... Opinion and gain insight from other stock traders and investors of Brainstorm Cell Therapeutics need to know the! Priced at $ 5.52 after the most recent trading session with less advanced disease float of 25.30M and shorts... Research before you hear about it on CNBC and others conducting clinical trials to evaluate efficacy! Pre-Specified subgroup of patients with less advanced disease now to get the hottest to. Conducting clinical trials to evaluate the efficacy and safety in ALS and in progressive MS and currently shorts hold 23.59. They have provided for BCLI stock was down 66.4 % as of noon.... The next time I comment to trade every day before the market of patients with less advanced disease,! 15 % for its drug compared to 15 % for the next time comment... Stock traders and investors the efficacy and safety in ALS and in progressive MS was to.